These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 33928588)

  • 21. Journey of siRNA: Clinical Developments and Targeted Delivery.
    Nikam RR; Gore KR
    Nucleic Acid Ther; 2018 Aug; 28(4):209-224. PubMed ID: 29584585
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of RNA interference-based therapeutics and application of multi-target small interfering RNAs.
    Li T; Wu M; Zhu YY; Chen J; Chen L
    Nucleic Acid Ther; 2014 Aug; 24(4):302-12. PubMed ID: 24796432
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Growing Class of Novel RNAi Therapeutics.
    Traber GM; Yu AM
    Mol Pharmacol; 2024 Jun; 106(1):13-20. PubMed ID: 38719476
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Ocular Gene Delivery Landscape.
    Sahu B; Chug I; Khanna H
    Biomolecules; 2021 Aug; 11(8):. PubMed ID: 34439800
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Small interfering RNA-mediated gene suppression as a therapeutic intervention in hepatocellular carcinoma.
    Hajiasgharzadeh K; Somi MH; Shanehbandi D; Mokhtarzadeh A; Baradaran B
    J Cell Physiol; 2019 Apr; 234(4):3263-3276. PubMed ID: 30362510
    [TBL] [Abstract][Full Text] [Related]  

  • 26. siRNA therapeutics: a clinical reality.
    Saw PE; Song EW
    Sci China Life Sci; 2020 Apr; 63(4):485-500. PubMed ID: 31054052
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting.
    De Paula D; Bentley MV; Mahato RI
    RNA; 2007 Apr; 13(4):431-56. PubMed ID: 17329355
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advances in siRNA therapeutics and synergistic effect on siRNA activity using emerging dual ribose modifications.
    Gangopadhyay S; Gore KR
    RNA Biol; 2022 Jan; 19(1):452-467. PubMed ID: 35352626
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Noncoding RNA for Cancer Gene Therapy.
    Zhong X; Zhang D; Xiong M; Zhang L
    Recent Results Cancer Res; 2016; 209():51-60. PubMed ID: 28101687
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs.
    Aigner A
    J Biotechnol; 2006 Jun; 124(1):12-25. PubMed ID: 16413079
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical advances of siRNA therapeutics.
    Hu B; Weng Y; Xia XH; Liang XJ; Huang Y
    J Gene Med; 2019 Jul; 21(7):e3097. PubMed ID: 31069898
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gene Silencing using siRNA for Preventing Liver Ischaemia-Reperfusion Injury.
    Marinho HS; Marcelino P; Soares H; Corvo ML
    Curr Pharm Des; 2018; 24(23):2692-2700. PubMed ID: 30084326
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Research progress on the development of the strategies for siRNAs delivery in vivo].
    Tang D; Mao A
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2012 Aug; 29(4):775-9. PubMed ID: 23016434
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung.
    Günther M; Lipka J; Malek A; Gutsch D; Kreyling W; Aigner A
    Eur J Pharm Biopharm; 2011 Apr; 77(3):438-49. PubMed ID: 21093588
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthetic nanocarriers for the delivery of polynucleotides to the eye.
    Saraiva SM; Castro-López V; Pañeda C; Alonso MJ
    Eur J Pharm Sci; 2017 May; 103():5-18. PubMed ID: 28263915
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Progress in RNAi-based antiviral therapeutics.
    Zhou J; Rossi JJ
    Methods Mol Biol; 2011; 721():67-75. PubMed ID: 21431679
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic potential of chemically modified siRNA: Recent trends.
    Selvam C; Mutisya D; Prakash S; Ranganna K; Thilagavathi R
    Chem Biol Drug Des; 2017 Nov; 90(5):665-678. PubMed ID: 28378934
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates.
    Brown KM; Nair JK; Janas MM; Anglero-Rodriguez YI; Dang LTH; Peng H; Theile CS; Castellanos-Rizaldos E; Brown C; Foster D; Kurz J; Allen J; Maganti R; Li J; Matsuda S; Stricos M; Chickering T; Jung M; Wassarman K; Rollins J; Woods L; Kelin A; Guenther DC; Mobley MW; Petrulis J; McDougall R; Racie T; Bombardier J; Cha D; Agarwal S; Johnson L; Jiang Y; Lentini S; Gilbert J; Nguyen T; Chigas S; LeBlanc S; Poreci U; Kasper A; Rogers AB; Chong S; Davis W; Sutherland JE; Castoreno A; Milstein S; Schlegel MK; Zlatev I; Charisse K; Keating M; Manoharan M; Fitzgerald K; Wu JT; Maier MA; Jadhav V
    Nat Biotechnol; 2022 Oct; 40(10):1500-1508. PubMed ID: 35654979
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Editorial focus: understanding off-target effects as the key to successful RNAi therapy.
    Bartoszewski R; Sikorski AF
    Cell Mol Biol Lett; 2019; 24():69. PubMed ID: 31867046
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics.
    Kulkarni JA; Witzigmann D; Chen S; Cullis PR; van der Meel R
    Acc Chem Res; 2019 Sep; 52(9):2435-2444. PubMed ID: 31397996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.